Compare Inovio Pharmaceuticals Inc (INO) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.74B). The key difference: Nuvation Bio Inc. Class A Common Stock is far larger — about 15.5× Inovio Pharmaceuticals Inc's market cap, and Nuvation Bio Inc. Class A Common Stock is more actively traded (9,289,619 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| INO | NUVB | |
|---|---|---|
Market Cap | $112.19M | $1.74B |
Volume | 3,201,278 | 9,289,619 |
Sector | Health | Health |
52-Week High | $2.65 | $9.54 |
52-Week Low | $0.66 | $3.41 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $83.51M | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
